1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Advanced BioHealing hopes for $200 million in IPO

 
• By Nancy Faigen

Advanced BioHealing, a regenerative medicine company developing and commercialising living cell therapies, has filed an initial public offering with US regulators, hoping to raise $186-213 million before deductions part of which will be spent on a second manufacturing facility and part of which may be used for in-licensing or acquisitions. The issue puts for 13.35 million shares on the table with the company hoping for a share price between $14 and $16 each.

Advanced BioHealing, a regenerative medicine company developing and commercialising living cell therapies, has filed an initial public offering with US regulators, hoping to raise $186-213 million before deductions part of which will be spent on a second manufacturing facility and part of which may be used for in-licensing or acquisitions. The issue puts for 13.35 million shares on the table with the company hoping for a share price between $14 and $16 each.

The company, based in Westport, Connecticut, markets the tissue-engineered substitute Dermagraft, which assists in restoring damaged tissue and is currently...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

UCB Takes A Bow as Bimzelx HS Launch Achieves Lift-Off

 
• By Manas Mishra

The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 
• By Alaric DeArment

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist boosts its sales force ahead of the launch of Anzupgo.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

More from Therapeutic Category

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.